1Allen RP ,Pieehietti D,Hening WA ,et al. Restless legs syndrome: diagnostic criteria,special considerations,and epidemiology A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health[J]. Sleep Med, 2003,4(2) : 101-119.
2Scha Pira AH. Restless legs Syndrome :an update on treatment options [J]. Drugs, 2004,64 (2) : 149-158.
3Clemens S,Hoehman S. Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-outmice[J]. J Neurosc, 2004,24 : 11337-11345.
4Mont Plaisir J ,Nieolas A ,Denesle R ,et al. Restless legs syndrome improved by PramPexole :a double blind randomized trial[J]. Neurology, 1999,52(5) :938-943.
6Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health [J]. Sleep Med, 2003, 4(2): 101-119.
7Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome[J]. Neurology, 2006, 67(6)..1 034-1 039.
8Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep:a randomized, double-blind, placebo-controlled trial[J]. Sleep Med, 2009, (8) : 874-881.
9Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study [J]. J Neurol, 2006, 253(5):601-607.
10Lemke MR, Brecht HM, Koester J, et al. Effects of the do pamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease[J]. J Neurol,2006, 253 (1) :266-270.
